NEW YORK (GenomeWeb) – The Structural Genomics Consortium and the CHDI Foundation have struck an agreement to discover and characterize new drug targets for Huntington's disease and to make their findings available for use by academic researchers and pharmaceutical and biotechnology companies.

Neither the SGC nor CHDI will file for patents on any of their research findings, but will make all the reagents and knowledge they generate widely available without restrictions, the partners said yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.